相似文献
1
EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.
Oncogene. 2014 Jan 9;33(2):173-80. doi: 10.1038/onc.2012.579. Epub 2013 Jan 14.
2
ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
Cell Commun Signal. 2019 Jul 10;17(1):74. doi: 10.1186/s12964-019-0388-5.
3
Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.
Am J Pathol. 2014 Jul;184(7):2082-98. doi: 10.1016/j.ajpath.2014.04.006. Epub 2014 May 13.
4
Malignant peripheral nerve sheath tumor invasion requires aberrantly expressed EGF receptors and is variably enhanced by multiple EGF family ligands.
J Neuropathol Exp Neurol. 2013 Mar;72(3):219-33. doi: 10.1097/NEN.0b013e3182859939.
5
ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors.
Anticancer Res. 2022 May;42(5):2327-2340. doi: 10.21873/anticanres.15712.
6
Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma.
Mol Med Rep. 2015 Jul;12(1):498-502. doi: 10.3892/mmr.2015.3439. Epub 2015 Mar 5.
7
Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis.
Mol Cell Biol. 2003 Mar;23(6):2213-24. doi: 10.1128/MCB.23.6.2213-2224.2003.
8
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
J Pathol. 2010 Jan;220(1):58-70. doi: 10.1002/path.2633.
9
An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.
EBioMedicine. 2016 Jul;9:110-119. doi: 10.1016/j.ebiom.2016.06.007. Epub 2016 Jun 4.
10
Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Clin Cancer Res. 2019 Jul 1;25(13):4117-4127. doi: 10.1158/1078-0432.CCR-18-3224. Epub 2019 Apr 1.
引用本文的文献
1
From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors.
Cell Oncol (Dordr). 2025 Apr 2. doi: 10.1007/s13402-025-01054-9.
2
Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development.
Neurooncol Adv. 2025 Feb 16;7(1):vdaf040. doi: 10.1093/noajnl/vdaf040. eCollection 2025 Jan-Dec.
3
Two Small Peptides from Hydrolysates Exhibit Antitumor Activity Through Inhibition of TNF-α-Mediated Signal Transduction Pathways.
Life (Basel). 2025 Jan 15;15(1):105. doi: 10.3390/life15010105.
4
Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents.
Target Oncol. 2024 Sep;19(5):665-678. doi: 10.1007/s11523-024-01078-5. Epub 2024 Jul 2.
5
PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.
Pharmaceuticals (Basel). 2024 May 27;17(6):685. doi: 10.3390/ph17060685.
6
Curcumin and its Analogues in Oral Squamous Cell Carcinoma: State-of-the-art and Therapeutic Potential.
Anticancer Agents Med Chem. 2025;25(5):313-329. doi: 10.2174/0118715206297840240510063330.
7
The therapeutic potential of neurofibromin signaling pathways and binding partners.
Commun Biol. 2023 Apr 20;6(1):436. doi: 10.1038/s42003-023-04815-0.
8
Comprehensive pan-cancer analysis of STAT3 as a prognostic and immunological biomarker.
Sci Rep. 2023 Mar 28;13(1):5069. doi: 10.1038/s41598-023-31226-2.
9
Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management.
Cancers (Basel). 2023 Feb 8;15(4):1077. doi: 10.3390/cancers15041077.
10
Matrix protein Tenascin-C promotes kidney fibrosis via STAT3 activation in response to tubular injury.
Cell Death Dis. 2022 Dec 15;13(12):1044. doi: 10.1038/s41419-022-05496-z.
本文引用的文献
1
Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.
Transl Oncogenomics. 2012;5:1-7. doi: 10.4137/TOG.S8830. Epub 2012 Jan 18.
2
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32. doi: 10.1002/gcc.20921. Epub 2011 Aug 24.
3
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.
J Clin Invest. 2011 Jul;121(7):2723-35. doi: 10.1172/JCI44745.
4
Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Clin Cancer Res. 2011 Jun 15;17(12):3943-55. doi: 10.1158/1078-0432.CCR-11-0193. Epub 2011 May 3.
5
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
Cancer Cell. 2011 Apr 12;19(4):498-511. doi: 10.1016/j.ccr.2011.03.004.
6
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.
Cancer Cell. 2011 Apr 12;19(4):456-69. doi: 10.1016/j.ccr.2011.03.009.
7
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.
Cancer Cell. 2011 Apr 12;19(4):441-55. doi: 10.1016/j.ccr.2011.03.002.
8
Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Cancer Res. 2010 Mar 15;70(6):2445-54. doi: 10.1158/0008-5472.CAN-09-2468. Epub 2010 Mar 9.
9
The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
Cancer Res. 2010 Feb 15;70(4):1356-66. doi: 10.1158/0008-5472.CAN-09-2178. Epub 2010 Feb 2.
10
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.
EMBO Mol Med. 2009 Jul;1(4):236-48. doi: 10.1002/emmm.200900027.
Zotero 插件